A large-scale clinical trial conducted by the World Health Organization has determined that Gilead Sciences Inc.’s remdesivir had little or no effect on COVID-19 patients’ chances of survival or length of hospital stay. The antiviral drug had been granted Emergency Use Authorization (EUA) by the Food and Drug Administration inread more